PD-1 immunobiology in glomerulonephritis and renal cell carcinoma

Colleen S Curran1, Jeffrey B Kopp2

  • 1Critical Care Medicine Department, Clinical Center, NIH, BG 10 RM 2C135, 10 Center Drive, Bethesda, MD, 20814, USA. colleen.curran@nih.gov.

BMC Nephrology
|March 7, 2021
PubMed
Abstract

Insights

Programmed cell death protein 1 (PD-1) interactions are crucial in kidney health and disease. Dysregulation of PD-1:PD-L1 pathways impacts kidney diseases like glomerulopathies and renal cell carcinoma (RCC), affecting immunotherapy responses.

Area of Science:

  • Immunology
  • Nephrology
  • Oncology

Background:

  • Programmed cell death protein 1 (PD-1) receptors and ligands maintain kidney immunological balance.
  • Dysregulated PD-1:PD-L1 interactions are implicated in glomerulopathies and renal cell carcinoma (RCC) pathogenesis.
  • Understanding PD-1 regulation in the kidney is vital for PD-1/PD-L1 immunotherapies and managing adverse events like glomerulopathies.

Purpose of the Study:

  • To review the expression and function of PD-1 molecules in healthy kidneys, PD-1 immunotherapy-induced nephrotoxicity, glomerulopathies, and RCC.
  • To compare PD-1 axis functions in glomerulopathies and RCC.
  • To explore potential regulatory pathways of the PD-1 axis in kidney disease.

Main Methods:

  • Literature review focusing on PD-1 expression and function in various kidney conditions.
  • Comparative analysis of PD-1 axis roles in glomerulopathies and RCC.
  • Examination of cellular and molecular pathways regulating PD-1.

Main Results:

  • PD-1 and its ligands are expressed on various kidney cells, including immune cells and renal proximal tubule epithelial cells.
  • Vitamin D3, glutathione, and AMP-activated protein kinase (AMPK) regulate PD-1 expression and function via hypoxic cell signals.
  • Altered pathways in kidney disease link to factors like VEGF, erythropoietin, adiponectin, IL-18, IL-23, and chemokines, with differential production in glomerulonephritis and RCC.

Conclusions:

  • Similar chemokines are involved in immune cell recruitment in glomerulopathies and RCC, while distinct mediators affect T cell differentiation.
  • Further research is needed on PD-1 and PD-1 ligand expression and function in diseased kidney tissue, especially on double-negative T cells and parenchymal cells.
  • Regulation of the PD-1 axis by Vitamin D3, glutathione, and/or AMPK may be significant for kidney disease progression and immunotherapy response.